Terwogt J M, Nuijen B, Huinink W W, Beijnen J H
Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Cancer Treat Rev. 1997 Mar;23(2):87-95. doi: 10.1016/s0305-7372(97)90022-0.
Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a 1:1 (v/v) mixture of ethanol and Cremophor EL. This formulation, however, has been demonstrated to cause some severe hypersensitivity reactions. Therefore the development of a safer intravenous formulation devoid of Cremophor EL is an important investigational issue. This review deals with some of the most promising formulation alternatives.
紫杉醇是一种新型抗肿瘤药物，临床上对晚期卵巢癌和乳腺癌具有活性，目前正在对其他多种癌症进行研究。与静脉注射紫杉醇相关的问题之一是其在水中的溶解度低。目前的药物制剂由乙醇和聚氧乙烯蓖麻油（Cremophor EL）按1:1（v/v）的比例混合而成。然而，这种制剂已被证明会引起一些严重的过敏反应。因此，开发一种不含聚氧乙烯蓖麻油（Cremophor EL）的更安全的静脉制剂是一个重要的研究课题。本综述探讨了一些最有前景的制剂替代方案。
